Salmonella Typhi Haplotype 58 (H58) Biofilm Formation and Genetic Variation in Typhoid Fever Patients with Gallstones in an Endemic Setting in Kenya

The causative agent of typhoid fever, Salmonella enterica serovar Typhi, is a human restricted pathogen. Human carriers, 90% of whom have gallstones in their gallbladder, continue to shed the pathogen after treatment. The genetic mechanisms involved in establishing the carrier state are poorly understood, but S. Typhi is thought to undergo specific genetic changes within the gallbladder as an adaptive mechanism. In the current study, we aimed to identify biofilm forming ability and the genetic differences in longitudinal clinical S. Typhi isolates from asymptomatic carriers with gallstones in Nairobi, Kenya. Whole genome sequences were analyzed from 22 S. Typhi isolates, 20 from stool and 2 from blood samples, all genotype 4.3.1 (H58). Nineteen strains were from four patients also diagnosed with gallstones, of whom, three had typhoid symptoms and continued to shed S. Typhi after treatment. All isolates had point mutations in the quinolone resistance determining region (QRDR) and only sub-lineage 4.3.1.2EA3 encoded multidrug resistance genes. There was no variation in antimicrobial resistance patterns among strains from the same patient/household. Non-multidrug resistant (MDR), isolates formed significantly stronger biofilms in vitro than the MDR isolates, p<0.001. A point mutation within the treB gene (treB A383T) was observed in strains isolated after clinical resolution from patients living in 75% of the households. Missense mutations in Vi capsular polysaccharide genes, tviE P263S was also observed in 18% of the isolates. This study provides insights into the role of typhoid carriage, biofilm formation, AMR genes and genetic variations in S. Typhi from asymptomatic carriers.


Introduction
Typhoid fever (typhoid), a life-threatening systemic infection caused predominantly by Salmonella enterica subspecies enterica serotype Typhi (S.Typhi), remains a common infection and a public health concern in resource poor-settings in parts of sub-Saharan Africa and Asia (1)(2)(3)).An estimated 9 million new typhoid fever cases occur each year, of which 2-3% results in death even with adequate antibiotics therapy (4,5).Typical symptoms manifest between 1 and 3 weeks postinfection and encompass elevated prolonged fever, headache, malaise, abdominal pain, diarrhea, constipation, hypersplenism and rose-colored spots on the chest (6).S. Typhi is transmitted via the fecal-oral route in settings with poor standards of sanitation, low levels of hygiene and inadequate water supply (7,8).Besides inadequate resources, typhoid endemic settings lack a quality public health infrastructure (9).
Upon ingestion of contaminated food or water, S. Typhi bacteria that survive the hostile gastric acid rich environment in the stomach, are able to replicate in the new host (9,10).The typhoid bacilli can invade the intestinal mucosa, typically through microfold (M) cells, and establish an initially clinically undetectable infection involving significant systemic dissemination and a transient primary bacteremia (9).S. Typhi also reach the gallbladder hematogenously during primary bacteremia or shortly thereafter through infected hepatic bile entering the gallbladder (11,12).S. Typhi bacteria can survive, replicate and evade immune surveillance intracellularly within a modified phagosome known as Salmonella-containing vacuole (SCV) (13,14).
Although the majority of patients recover from typhoid fever after an appropriate treatment, some individuals become asymptomatic carriers and shed the infectious typhoid bacilli intermittently in their faeces for an ill-defined period of time after apparent clinical resolution.Since the early 20 th century, asymptomatic carriage has been demonstrated to be a source of transmission of typhoid fever, including in the famous case of Mary Mallon (15).Generally, ~2-5% of acute typhoid cases fail to clear the infection fully within one year and develop asymptomatic chronic carriage (16)(17)(18).Approximately 90% of typhoid chronic carriers have gallstones in their gallbladder (19,20).
Persistent colonization of the gallbladder by S. Typhi is facilitated by formation of biofilms on the surface of cholesterol gallstones (19,21).Biofilms are organized three-dimensional multicellular communities encased in self-produced extracellular polymeric substances (EPS) comprised of polysaccharides, extracellular DNA [eDNA], proteins and lipids (22).Biofilms account for 80% of chronic infections in humans, leading to increased rates of hospitalization, high health care .costs, and increased mortality and morbidity rates (23).Bacteria in a biofilm are protected from certain environmental stresses, such as osmotic shifts, oxidative stress, metal toxicity, dehydration, radiation, host immunity, antimicrobial agents, and disinfectants (24).Chronic S. Typhi colonization usually cannot be resolved with antibiotics; gallbladder resection is the only option, although not always effective (21).Biofilm formation leads to continuous shedding and reattachment of planktonic cells, followed by bacteria diffusion in urine and feaces (19,25).Since S. Typhi is a human-restricted pathogen, gallbladder colonization and fecal shedding form a central dogma for further transmission and persistence of typhoid fever.
In the gallbladder, S. Typhi is exposed to bile, a complex digestive secretion comprised of bile acids, bilirubin, phospholipids and cholesterol, that exhibit strong antimicrobial properties (26,27).
The molecular mechanisms involved in establishing the carrier state are poorly understood; however S. Typhi is thought to undergo genetic changes within the gallbladder as an adaptive mechanism (21,28,29).
Although it is widely accepted that S. Typhi carriers contribute to typhoid transmission in endemic settings, little progress has been made in understanding typhoid carrier state.The current study, we aimed at identifying the genetic differences in longitudinal clinical S. Typhi isolates from carriers, in a typhoid endemic setting in Nairobi, Kenya.

Genotype Identification and Clustering Tree
Since the S. Typhi population is highly structured, with dozens of subclades being associated with specific geographical regions and antimicrobial resistance patterns, the genotypes causing asymptomatic carriage in the current study settings were identified.All 22 bacteria isolates were from and index case while isolate (vi) was from a household contact.Isolates (i) and (ii), household B, were from index case while (iii), (iv) and (v) were from an asymptomatic household contact living with the index case.All the S. Typhi strains were isolated from stool samples apart from two, isolate (i) from household B, and isolate (i) from household D, which were isolated from blood samples.The time of isolation/shedding of each isolate is shown in Table 1.Assembled genomes can be accessed in NCBI database, BioProject ID PRJNA1101423, GenBank accession numbers are shown in the data availability section.
Table 1.Time of isolation/shedding of S. Typhi.

Household
Category of Study participant Time of isolation of S. Typhi isolates (No. of days after the index case was diagnosed with typhoid fever)

Antimicrobial Resistance Genes
Different antimicrobial resistance patterns were observed in the isolated S. Typhi strains.The seven isolates belonging to sub-lineage 4.3.1.2EA3(from Household D) were multidrug resistant, all expressed the following acquired antimicrobial resistance genes; sul1, dfrA7, catA1, aph(6)-Id, aph(3'')-Ib, sul2 and blaTEM-1, and a point mutation in the Quinolone Resistance Determining Region (QRDR) of gyrA (gyrA S83Y).Phenotypic susceptibility data showed that these seven isolates were resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole and nalidixic acid but non-susceptible to ciprofloxacin.The four sub-lineage 4.3.1.2EA2isolates (S. Typhi strains from Household C) had a gyrB S464F mutation in the QRDR, and all were nonsusceptible to nalidixic acid and ciprofloxacin according to phenotypic susceptibility results.The third group, lineage 4.3.1.1,had six strains (Household A isolates) with a gyrB S464F mutation, also demonstrating non-susceptibility to nalidixic acid and ciprofloxacin.The other five lineage 4.3.1.1 strains (household B isolates) had gyrA S83F mutations in the QRDR, and showed resistance to nalidixic acid and non-susceptibility to ciprofloxacin (Table 2).  3 and Supplementary files 2 and 3).The second and third follow-up isolates from the same patient (C iii and C iv) had two silent mutations, one in the yccC gene that codes for putative membrane protein YccC and tehA gene that codes for dicarboxylate transporter/tellurite-resistance protein TehA (tehA A124A and yccC R199R mutations respectively) and missense mutations in the amiA gene that codes for N-acetylmuramoyl-L-alanine amidase AmiA (amiA V145A mutation).An additional mutation was observed in the LEJNAJ_18700 locus (K124E) that encodes for 4-hydroxyphenylacetate permease.The second follow-up isolate from the patient in household C (C iii) had a third missense mutation in the LEJNAJ_10515 locus (D78G) that encodes phage baseplate assembly protein V.The follow-up lineage 4.3.1.1 strains, which were isolated from households A and B, also had a few mutations.While no mutation was detected in the first follow-up sample from the index case in household A, the second follow-up sample (A iii) had a single nucleotide polymorphism in the crl gene (crl L38P), crl codes for sigma factor-binding protein Crl.The third and fourth follow-up S. Typhi isolates from the same patient (A iv and A v) had a silent mutation in the tnpA gene (tnpA Y41Y) that codes for IS200/IS605 family transposase (Supplementary file 1).From the same household, an S. Typhi strain isolated from a household contact's stool sample (A vi) had a missense mutation in the treB gene (treB A383T).S. Typhi bacteria isolated from the stool of the index case living in household B before treatment (isolate ii), had a missense mutation in the waaK gene (waaK P167L) that codes for lipopolysaccharide Nacetylglucosaminyltransferase, compared to the strain from blood sample collected on the same day (Supplementary file 2).
.    4), None of these plasmids had identifiable AMR genes, but isolates in these subgroups formed significantly stronger biofilms in the presence of both cholesterol and human bile (Figure 2C).However, there was no statistical significance in biofilm forming ability in strains isolated during the symptomatic vs. asymptomatic stage in each of the three sub-groups of S. Typhi (Figure 2D).

Discussion
Although typhoid fever has largely been eliminated in high income countries, it remains a major global public health concern especially among low-and middle-income countries (2).The haplotype 58 (H58), which is associated with antimicrobial resistance has also been reported from other parts of sub-Saharan Africa and Southeast Asia (30,31).In this study, H58 (genotype 4. is the first study comparing biofilm forming ability in different S. Typhi lineages.The mechanism leading to differences in biofilm formation in isolates from the same genotype will need to be further investigated. Genetic variations were observed in S. Typhi from asymptomatic carriers, with a treB A383T point mutation being observed in at least one isolate from each of the four households.The treB gene .codes for PTS trehalose transporter subunit IIBC.As seen in Table 3, household B, some of the mutations observed in the first follow-up isolate were not detected in S. Typhi strains isolated during the consecutive follow-ups.However, some mutations were observed in more than one strain isolated from the same patient.From the patient shedding sub-lineage 4.3.1.2EA3strains, the tviE P263S mutation was observed in the fourth isolate and all strains isolated thereafter.This suggests that some of the mutations are maintained in the population during the asymptomatic carriage, while others are not.Although no strain was isolated directly from gallbladder in our study, mutations in the tviE gene was also observed in S. Typhi gallbladder genome sequences in a previous study (29).The tviE gene facilitates the polymerization and translocation of the Vi capsule (35).Vi capsular polysaccharide, an antiphagocytic capsule, covers the surface of S. Typhi allowing it to selectively evade phagocytosis by human neutrophils while promoting human macrophage phagocytosis (36).This crucial virulence factor in S. Typhi (Vi) also plays a key role in the development of vaccines against typhoid fever (37).However, additional research will be required to understand if this mutation alters the expression of Vi antigen to benefit S. Typhi pathogenesis or chronic carriage.
The main limitation in this study is lack of availability of isolates from gallbladder samples from patients shedding S. Typhi for comparison with those isolated from stool and blood samples.There were also no S. Typhi belonging to other genotypes for comparison purposes.

Conclusion
The resistance patterns in S. Typhi did not change during the duration of asymptomatic carriage in study participants, but these individuals continued to shed and transmit drug resistant strains of this pathogen.Mutations in S. Typhi were observed to occur during carriage including those in the Vi antigen locus.Sub-lineages analyzed in this study that were not multidrug resistant, showed the ability to form stronger biofilms than the multidrug resistant strains.This study provides some insights into mutations, drug resistance and biofilm formation during typhoid carriage, and this information may be used to influence public health approaches aimed at reducing carriage and transmission of S. Typhi.

Source of Bacteria strains
The whole genome sequences of 22 S. Typhi strains isolated from blood and stool samples of six patients living in four different households in Mukuru informal settlement, a typhoid endemic area in Nairobi, Kenya, were analyzed.Nineteen of these strains were from four patients who were also diagnosed with cholelithiasis, of whom, three had typhoid symptoms and continued to shed S.
Typhi after treatment.The presence of gallstones was confirmed through an ultrasound scan, the primary imaging modality performed by a radiologist used to evaluate patients suspected of having gallbladder disease.One of the patients with gallstones was asymptomatic but shedding S. Typhi and living in the same household (household B) with an acute typhoid fever case (not diagnosed with gallstones).In a different household (household A), a study participant (household contact) not diagnosed with cholelithiasis shed S. Typhi once.The index case from this household was diagnosed with cholelithiasis and continued to shed S. Typhi after treatment with antibiotics.
Laboratory methods on isolation and identification of the isolates are as described in our previous publication (38).

Whole Genome Sequencing
DNA extracted from S. Typhi strains using GenElute™ Bacterial Genomic DNA Kit (Missouri, United States) was prepared for whole genome sequencing by SeqCoast Genomics using an Illumina DNA Prep tagmentation kit and unique dual indexes.Sequencing was performed on the Illumina NextSeq2000 platform using a 300-cycle flow cell kit to produce 2x150bp paired reads as previously described (39).PhiX control, 1-2%, was spiked into the run to support optimal base calling.Read demultiplexing, read trimming, and run analytics were performed using DRAGEN v3.10.12, an on-board analysis software on the NextSeq2000.Raw sequencing data generated during this study are available in the National Center for Biotechnology Information (NCBI) public data, BioProject ID PRJNA1101423.

Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was performed using the disk diffusion technique for all antimicrobials commonly used in Kenya for typhoid fever treatment including ampicillin (10 µg), tetracycline ( The results were compared with phenotypic susceptibility data.

Variant Calling
To identify genetic variations between the longitudinal clinical isolates, S. Typhi strains isolated before each typhoid index case was treated with antibiotics were used as the reference genome, and were compared with those isolated after treatment (follow-up isolates), and/or those isolated from household contacts using breseq (58).The variant calling pipeline was as follows; qualityfiltering of raw reads using Trimmomatic (40), mapping of reads against a reference genome (first strain isolated from the index case), analysis of possible mutations based on mapping data, identification of mutations and graphical and tabular summaries of mutation profile across samples (42).

Plasmid Identification
To identify plasmids in the isolated S. Typhi strains, a plasmid detection tool PLASMe was used (https://github.com/HubertTang/PLASMe).The tool uses the alignment component in PLASMe to identify closely related plasmids while diverged plasmids are predicted using order-specific Transformer models (59).

In Vitro Biofilm Formation Assays
Because of the importance of biofilm formation on gallstones in chronic carriage (17,19) the biofilm forming ability of all the 22 human S. Typhi isolates were tested under gallbladder simulating conditions.S. Typhi biofilms were grown on non-treated polystyrene 96-well plates (Corning, Kennebunkport, ME).To simulate growth conditions on gallstones, wells in two plates were pre-coated with cholesterol by adding a solution of 5 mg/mL in 1: Student's t-test was used to test level of significance in biofilm formation in strains isolated before treatment vs last strains shed by the patient, P-values less than 0.05 (P<0.05) were considered significant. .

Figure 1 .
Figure 1.Clustering tree for S. Typhi strains isolated from the study participants living in the different households as generated using the pathogenwatch database and visualized using microreact.Roman numbers indicate specific isolates from the different households (A, B, C and D).Isolates from each household are shown by specific leaf nodes color.Branch tips are colorcoded according to the household of isolation.The bar represents branch length scale bar.The tree can be visualized here https://microreact.org/project/s3biz8PE9LDnFayjco22MZ-s-typhi-kenya-2023.
1 isopropanol:ethanol and air-dried overnight.A pure colony of S. Typhi on an XLD agar plate was cultured in Tryptone Soy Broth (TSB).Overnight (O/N) cultures in broth were normalized to OD600=0.8, diluted 1:2500 in TSB or TSB containing 2.5% human bile, and 100 µL/well were dispensed into the plates.The plates were incubated at 25°C in a Fisherbrand™ nutating mixer (Thermo Fisher Scientific; Hampton, NH) at 24 rpm for 96 hours.Media (TSB or TSB containing bile) was changed after every 24 hours for consistent S. Typhi biofilm growth.Plates were emptied on the fourth day and washed twice before heat fixing at 60°C for 1 hour.The biofilms were stained using a crystal violet solution and acetic acid (33%) used to elute crystal violet before reading the OD570.GraphPad prism 9.5 was used to analyze the biofilm formation results.One way Analysis of variance (ANOVA) was used to test level of significance in biofilm formation between the different S. Typhi sub-lineages and in different conditions, i.e., biofilms in absence of cholesterol and bile, in cholesterol coated plates in absence of bile, and in presence of cholesterol and bile.
Patients with gallstones in their gallbladder.Index cases had symptoms at the time of recruitment while household contacts were asymptomatic and living with a typhoid fever acute case

Table 2 .
Antibiotic resistance profiles in isolated S. Typhi.

Table 3 .
Missense mutations in S. Typhi strains isolated from index cases after apparent clinical resolution and from asymptomatic household contacts.

Table 4 .
Bacterial plasmids detected in isolated S. Typhi strains.
(34)33)st and South Asia as well as in East Africa and has spread globally(32,33).Three H58 east African subgroups (4.3.1.1EA1,4.3.1.2EA2,4.3.1.2EA3)previouslyreportedcirculating in the current study setting by our group (1), were the main lineages/sub-lineages shed by the cholelithiasis patients.The most abundant subgroup was 4.3.1.1EA1with11/22(50%) isolates, originating from individuals living in two different households.In one of these households, an acute case shed an S. Typhi belonging to the same sub-group as an asymptomatic household contact who was also diagnosed with gallstones.This suggests possible transmission of the pathogen by the carrier to the household contact (household B).From a different household, a typhoid patient also diagnosed with gallstones continued to shed sub-lineage 4.3.1.2EA2,whileinthe fourth household, S. Typhi sub-lineage 4.3.1.2EA3strainswereisolated from stool samples collected from an acute case after treatment.Unlike the other two sub-groups, the sub-lineage 4.3.1.2EA3Salmonellafromciprofloxacin(34).We hypothesize that the 4.3.1.1EA1and 4.3.1.2EA2sub-lineages form better biofilms to counteract the absence of antimicrobial resistance factors, or conversely, that lineage 4.3.1.2EA3has lost biofilm-related genes because it possesses more plasmids/genes encoding strong antimicrobial resistance.To the best of our knowledge, this 3.1)was identified as the single genotype shed by four cholelithiasis patients living in a typhoid endemic setting in Nairobi, Kenya.S. Typhi H58 is the most dominant genotype in many parts of .strains had MDR genes, showing resistance to ampicillin, sulfamethoxazole-trimethoprim and chloramphenicol.MDR isolates had more plasmids, 19, compared to the 14 plasmids in non-MDR isolates, from 4.3.1.1EA1and 15 plasmids from 4.3.1.2EA2.The seven sub-lineage 4.3.1.2EA3strains had the MDR genes detected in identified plasmids.All 22 S. Typhi isolates had point mutations in the QRDR, conferring reduced susceptibility to ciprofloxacin, a drug of choice for treating typhoid fever.There was no variation noted in antimicrobial resistance patterns among strains isolated from the patients in the same household.Multidrug resistance genes were not detected in 4.3.1.1EA1and 4.3.1.2EA2S. Typhi genomes, but the strains belonging to these subgroups formed significantly stronger biofilms as compared to the MDR sub-lineage 4.3.1.2EA3strains.Biofilms act as physical barrier protecting bacteria from killing by antimicrobials including antibiotics.A previous study demonstrated the role of biofilms in protecting